2024美国临床肿瘤学会（ASCO 2024）年会即将于2024年5月31日~6月4日在美国芝加哥举行。【肿瘤资讯】特别整理淋巴瘤重磅研究进展！
口头摘要专场（Oral Abstract Session）
摘要号：LBA7000
标题：Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study
BrECADD对比BEACOPP治疗晚期经典型霍奇金淋巴瘤的耐受性和疗效：GHSG HD21，一项随机研究
讲者：Peter Borchmann, University Hospital of Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)
摘要号：7001
标题：Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial
初治侵袭性ATL强化化疗后的早期allo-HSCT：JCOG0907，一项单臂Ⅲ期试验
讲者：Takuya Fukushima, University of the Ryukyus
摘要号：7002
标题：CLAMP: A phase Ⅱ prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.
卡瑞利珠单抗联合培门冬酶、依托泊苷和高剂量甲氨蝶呤治疗自然杀伤(NK)/ T细胞淋巴瘤的II期前瞻性研究
讲者：刘涛教授，华中科技大学同济医学院附属协和医院
摘要号：LBA7003
标题：Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase Ⅲ DEB study
西达本胺联合R-CHOP治疗初治MYC和BCL2双表达弥漫大B细胞淋巴瘤：Ⅲ期DEB研究期中分析结果
讲者：赵维莅教授，上海血液学研究所
摘要号：7004
标题：Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells
Armored huCART19-IL18在CD19 CAR-T细胞治疗后发生疾病进展的复发/难治性淋巴瘤患者中的安全性和有效性
讲者：Jakub Svoboda, University of Pennsylvania
摘要号：LBA7005
标题：Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study
维布妥昔单抗联合来那度胺和利妥昔单抗治疗复发/难治性弥漫大B细胞淋巴瘤患者： ECHELON-3三期研究结果
讲者：Jeong A Kim, St. Vincent’s Hospital, The Catholic University of Korea
摘要号：7006
标题：Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
套细胞淋巴瘤患者一线接受苯达莫司汀联合利妥昔单抗治疗后继续使用利妥昔单抗的获益
讲者：Yucai Wang, Mayo Clinic
摘要号：7007
标题：Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study
SYMPATICO研究中伊布替尼联合维奈克拉治疗套细胞淋巴瘤和TP53突变患者的疗效和安全性
讲者：Michael Wang, The University of Texas MD Anderson Cancer Center
摘要号：7008
标题：Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase Ⅰ/Ⅱ study
格菲妥单抗单药治疗重度预处理的的复发/难治性套细胞淋巴瘤患者：来自Ⅰ/Ⅱ期研究的最新分析
讲者：Tycel Phillips, City of Hope National Medical Center
口头摘要速递专场（Rapid Oral Abstract Session）
摘要号：7009
标题：Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）的高危亚组中，伊布替尼+维奈克拉固定疗程治疗的疗效：CAPTIVATE Ⅱ期研究长达5.5年的随访结果
讲者：William Wierda, The University of Texas MD Anderson Cancer Center
摘要号：7010
标题：Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
来自国际血液和骨髓移植研究中心（CIBMTR）的Richter转化（RT）患者接受lisocabtagene maraleucel（liso- cell）治疗后的真实世界结果
讲者：Allison Winter, Cleveland Clinic Taussig Cancer Institute
摘要号：7011
标题：Examining two hematologic precursors and their impact on incident lymphoid malignancies
检测两种血液学前体及其对淋巴细胞恶性肿瘤的影响
讲者：Nicholas Boddicker, Mayo Clinic
摘要号：7012
标题：Randomized phase Ⅱ/Ⅲ study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701
R-CHOP+/-维奈克拉治疗初治MYC/BCL2双表达弥漫大B细胞淋巴瘤（DLBCL）的随机Ⅱ/Ⅲ期研究：Alliance A051701
讲者：Jeremy Abramson, Massachusetts General Hospital
摘要号：7013
标题：Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study
Lisocabtagene maraleucel（liso-cel）对比采用挽救性化疗（CT）和自体干细胞移植（ASCT）的标准疗法（SOC）作为R/R大B细胞淋巴瘤（LBCL）患者的二线（2L）治疗：随机Ⅲ期TRANSFORM研究的3年随访（FU）结果
讲者：Manali Kamdar, University of Colorado Cancer Center
摘要号：7014
标题：Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
既往未经治疗（1L）的滤泡性淋巴瘤（FL）患者接受Epcoritamab联合利妥昔单抗和来那度胺（R2）治疗，以及FL患者接受Epcoritamab维持治疗：EPCORE NHL-2第6和第7组
讲者：Leslie Lori, John Theurer Cancer Center, Hackensack Meridian Health
摘要号：7015
标题：EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL
EPCORE NHL-1滤泡性淋巴瘤（FL）周期（C）1优化（OPT）队列：扩大Epcoritamab在复发或难治性（R/R）FL中的临床应用
讲者：Julie Vose, University of Nebraska Medical Center
摘要号：7016
标题：Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)
Lisocabtagene maraleucel（liso-cel）治疗R/R套细胞淋巴瘤（MCL）患者： TRANSCEND NHL 001 MCL队列（TRANSCEND-MCL）中按既往全身治疗线数（LOT）和对既往布鲁顿酪氨酸激酶抑制剂（BTKi）的治疗反应进行的亚组分析
讲者：Maria Lia Palomba, Memorial Sloan Kettering Cancer Center
摘要号：7017
标题：Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity
Timdarpacept（IMM01）联合替雷利珠单抗治疗PD-1抑制剂治疗失败的经典型霍奇金淋巴瘤：一项评估安全性和初步抗肿瘤活性的开放标签、多中心Ⅱ期研究（IMM01-04）
讲者：宋玉琴教授，北京大学肿瘤医院
扫码关注专栏，与肿瘤资讯不见不散！
https://conferences.asco.org/am/abstracts
排版编辑：Mathilda
苏公网安备32059002004080号
